Table 2 Efficacy and parasite clearance time of the three treatment groups
Therapeutic response | AP (n = 110) | DHP (n = 55) | AL (n = 55) |
|---|---|---|---|
Excluded(%) | 0 | 0 | 0 |
Lost of follow-up (%) | 0 | 0 | 0 |
Early Treatment Failure(%) | 0 | 0 | 0 |
Late Clinical Failure(%, 95%CI) | 13(11.8, 5.79~17.85%) | 1(1.8, -1.71~5.34%) | 13(23.6,12.41~34.86%) |
ACPR (%, 95% CI) on D14 on D21 on D28 | 109 (99.1, 97.31~100.86%) 105(95.5, 91.56%~99.35%) 97(88.2, 82.15%~94.21%) | 55(100, 93.6%~100%) 55(100, 93.6%~100%) 54(98.2, 94.65~101.71%) | 54(98.2, 94.65~101.71%) 48(87.3, 78.46%~96.08%) 42(76.4, 65.14%~87.59%) |
ACPR by Intention-to-treat analysis on D28 (%) | 97/110 (88.2) | 54/55 (98.2) | 42/55 (76.4) |
ACPR adjusted by PCR on D28 (%) | 97/102*â–² (95.1) | 54/55 (98.2) | 42/51 (82.4) |
Parasite clearance time, mean ± SD hours | 66.7 ± 21.9*Δ | 65.6 ± 27.3Δ | 65.3 ± 22.5 |
Fever clearance time, mean ± SD hours | 31.6 ± 17.7*Δ | 34.6 ± 21.8 | 36.9 ± 15.4 |